BACKGROUND: Extrahepatic biliary stenosis (EBS) has malignant and benign causes. Patients with EBS are at risk of having or developing malignancy. Accurate diagnostic tests for early detection and surveillance are needed. The sensitivity of biliary cytology for malignancy is low. K-ras mutation analysis on brush cytology is a valuable adjunct, but specificity is low. A quantitative test for K-ras mutations has been developed: the amplification refractory mutation system (ARMS). AIM: To assess the test characteristics and additional value of ARMS in diagnosing the cause of EBS. METHODS: Brush samples from endoscopic retrograde cholangiopancreatography were collected from 312 patients with EBS. K-ras mutation analysis was performed using ARMS-allele specific amplification was coupled with real time fluorescent detection of PCR products. Results were compared with conventional cytology and K-ras mutation analysis using allele specific oligonucleotide (ASO) hybridisation, and evaluated in view of the final diagnosis. RESULTS: The test characteristics of ARMS and ASO largely agreed. Sensitivity for detecting malignancy was 49% and 42%, specificity 93% and 88%, and positive predictive value (PPV) 96% and 91%, respectively. The sensitivity of ARMS and cytology combined was 71%, and PPV was 93%. The specificity of ARMS could be increased to 100% by setting limits for the false positives, but reduced sensitivity from 49% to 43%. CONCLUSIONS: ARMS can be considered supplementary to conventional cytology, and comparable to ASO in diagnosing malignant EBS. A specificity of 100% can be achieved with ARMS, which should be considered in the surveillance of patients at risk for pancreatic cancer.
BACKGROUND:Extrahepatic biliary stenosis (EBS) has malignant and benign causes. Patients with EBS are at risk of having or developing malignancy. Accurate diagnostic tests for early detection and surveillance are needed. The sensitivity of biliary cytology for malignancy is low. K-ras mutation analysis on brush cytology is a valuable adjunct, but specificity is low. A quantitative test for K-ras mutations has been developed: the amplification refractory mutation system (ARMS). AIM: To assess the test characteristics and additional value of ARMS in diagnosing the cause of EBS. METHODS: Brush samples from endoscopic retrograde cholangiopancreatography were collected from 312 patients with EBS. K-ras mutation analysis was performed using ARMS-allele specific amplification was coupled with real time fluorescent detection of PCR products. Results were compared with conventional cytology and K-ras mutation analysis using allele specific oligonucleotide (ASO) hybridisation, and evaluated in view of the final diagnosis. RESULTS: The test characteristics of ARMS and ASO largely agreed. Sensitivity for detecting malignancy was 49% and 42%, specificity 93% and 88%, and positive predictive value (PPV) 96% and 91%, respectively. The sensitivity of ARMS and cytology combined was 71%, and PPV was 93%. The specificity of ARMS could be increased to 100% by setting limits for the false positives, but reduced sensitivity from 49% to 43%. CONCLUSIONS: ARMS can be considered supplementary to conventional cytology, and comparable to ASO in diagnosing malignant EBS. A specificity of 100% can be achieved with ARMS, which should be considered in the surveillance of patients at risk for pancreatic cancer.
Authors: T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe Journal: J Gastrointest Surg Date: 2000 Nov-Dec Impact factor: 3.452
Authors: S J Clayton; F M Scott; J Walker; K Callaghan; K Haque; T Liloglou; G Xinarianos; S Shawcross; P Ceuppens; J K Field; J C Fox Journal: Clin Chem Date: 2000-12 Impact factor: 8.327
Authors: R H Bardales; M W Stanley; D D Simpson; S J Baker; C T Steele; R F Schaefer; C N Powers Journal: Am J Clin Pathol Date: 1998-05 Impact factor: 2.493
Authors: A C Tersmette; G M Petersen; G J Offerhaus; F C Falatko; K A Brune; M Goggins; E Rozenblum; R E Wilentz; C J Yeo; J L Cameron; S E Kern; R H Hruban Journal: Clin Cancer Res Date: 2001-03 Impact factor: 12.531
Authors: Christine A Iacobuzio-Donahue; Anirban Maitra; Grace L Shen-Ong; Tjarda van Heek; Raheela Ashfaq; Renee Meyer; Kimberly Walter; Karin Berg; Michael A Hollingsworth; John L Cameron; Charles J Yeo; Scott E Kern; Michael Goggins; Ralph H Hruban Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari Journal: Virchows Arch Date: 2008-09-18 Impact factor: 4.064
Authors: Benjamin R Kipp; Emily G Barr Fritcher; Amy C Clayton; Gregory J Gores; Lewis R Roberts; Jun Zhang; Michael J Levy; Kevin C Halling Journal: J Mol Diagn Date: 2010-09-23 Impact factor: 5.568